Author: admin

Graves’ Disease Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight

Graves’ Disease Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Graves’ Disease Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Graves’ Disease Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Graves’ Disease, historical and forecasted epidemiology as well as the Graves’ Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Graves’ Disease Market by downloading the comprehensive report from DelveInsight @ Graves’ Disease Treatment Market Size

 

Key Takeaways from the Graves’ Disease Market Report

  • In September 2024:- Immunovant Sciences GmbH- A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED). To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
  • In September 2024:- Amgen- The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period. The main objective of the study is to evaluate the effect of teprotumumab subcutaneous administration versus placebo on the proptosis responder rate (ie, the percentage of participants with a ≥ 2-mm reduction from Baseline in the study eye without deterioration [≥ 2-mm increase] of proptosis in the fellow eye) at Week 24.
  • As per DelveInsight’s estimates, Graves’ disease is the primary cause of hyperthyroidism, responsible for 60–80% of cases. Despite this prevalence, it is relatively uncommon, impacting roughly 1.2% of the US population.
  • According to American Thyroid Association (2024), more than 12% of the US population will develop a thyroid condition during their lifetime and an estimated 20 million Americans have some form of thyroid disease. Women are five to eight times more likely than men to have thyroid problems.
  • As per data from the National Institute of Diabetes and Digestive and Kidney Diseases (2021), Graves’ disease affects nearly 1 in 100 Americans.
  • According to Shang et al. (2024), an estimated 2.7–3.0% of the adult Chinese population—over 31 million individuals—are affected by one or more autoimmune diseases, a prevalence comparable to that seen in Western populations. The predominant contributors to this burden are autoimmune thyroid diseases and rheumatoid arthritis.
  • The leading Graves’ Disease Companies such as Apitope International NV, Quintiles Inc., European Commission, Immunovant Sciences GmbH, Novartis Pharmaceuticals, AV7 Limited, Medtronic, Pfizer, Sanguine Biosciences, Tourmaline Bio Inc., Horizon Pharma USA Inc., Viridian Therapeutics Inc., Innovent Biologics Co. Ltd, Hoffmann-La Roche and others.
  • Promising Graves’ Disease Therapies such as linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.

 

Gain a competitive edge in the Graves’ Disease Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Graves’ Disease Treatment Drugs

 

Graves’ Disease Epidemiology Segmentation in the 7MM

  • Graves’ Disease Gender-specific Cases
  • Total Graves’ Disease Prevalent Cases
  • Graves’ Disease Age Group-specific Cases
  • Total Graves’ Disease Treated Cases

 

Graves’ Disease Market Insights

Graves’ disease, an autoimmune disorder and the leading cause of hyperthyroidism, characterized by symptoms such as weight loss, rapid heartbeat, and in some cases, thyroid eye disease. While traditional treatments like anti-thyroid medications, radioactive iodine therapy, and thyroidectomy remain the cornerstone of management. Anti-thyroid drugs, such as methimazole and propylthiouracil (PTU), are commonly used to suppress thyroid hormone production, with Methimazole being the preferred first-line therapy due to its efficacy and safety profile. Radioactive iodine therapy is favored in the United States, especially when drug therapy is ineffective or contraindicated. It induces hypothyroidism, requiring thyroid hormone replacement. However, it is not recommended for patients with Graves’ ophthalmopathy or smokers due to potential risks.

 

Discover key developments and opportunities in the Graves’ Disease Market. Click here to learn more from DelveInsight’s latest report @ Graves’ Disease Market Size

 

Graves’ Disease Treatment Market

The DelveInsight’s Graves’ Disease treatment market report gives a thorough understanding of Graves’ Disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. The Graves’ Disease treatment market has experienced significant growth and evolution in recent years, reflecting the increasing prevalence of Graves’ disease, an autoimmune disorder that affects the thyroid gland. The Graves’ Disease treatment market has witnessed the advent of innovative treatment modalities, including anti-thyroid drugs, radioactive iodine therapy, and surgery

 

Graves’ Disease Companies and Therapies

  • Sling Therapeutics, Inc.: linsitinib
  • Immunovant Sciences GmbH: Batoclimab
  • Amgen: Teprotumumab
  • Viridian Therapeutics Inc.:- VRDN-001 10 mg/kg
  • Hoffmann-La Roche: Satralizumab

 

Download DelveInsight’s Graves’ Disease Market report today and stay ahead in this rapidly evolving field. @ Graves’ Disease Clinical Trials

 

Scope of the Graves’ Disease Market Report

  • Coverage- 7MM
  • Graves’ Disease Companies- Apitope International NV, Quintiles Inc., European Commission, Immunovant Sciences GmbH, Novartis Pharmaceuticals, AV7 Limited, Medtronic, Pfizer, Sanguine Biosciences, Tourmaline Bio Inc., Horizon Pharma USA Inc., Viridian Therapeutics Inc., Innovent Biologics Co. Ltd, Hoffmann-La Roche and others.
  • Graves’ Disease Therapies- linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.
  • Graves’ Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Graves’ Disease Unmet Needs, KOL’s views, Analyst’s views, Graves’ Disease Market Access and Reimbursement

 

Download the report to understand which factors are driving Graves’ Disease Market Trends @ Graves’ Disease Market Trends

 

Table of Content

1. Key Insights

2. Graves’ Disease Executive Summary

3. Competitive Intelligence Analysis for Graves’ Disease

4. Graves’ Disease: Market Overview at a Glance

5. Graves’ Disease: Disease Background and Overview

6. Patient Journey

7. Graves’ Disease Epidemiology and Patient Population

8. Graves’ Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Graves’ Disease Unmet Needs

10. Key Endpoints of Graves’ Disease Treatment

11. Graves’ Disease Marketed Products

12. Graves’ Disease Emerging Therapies

13. Graves’ Disease: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Graves’ Disease Market Outlook

16. Graves’ Disease Market Access and Reimbursement Overview

17. Graves’ Disease KOL Views

18. Graves’ Disease Market Drivers

19. Graves’ Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Graves’ Disease Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight

Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion

The Key Schizophrenia Companies in the market include – Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others.

 

DelveInsight’s “Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Schizophrenia, historical and forecasted epidemiology as well as the Schizophrenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Schizophrenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Schizophrenia Market Forecast

 

Some of the key facts of the Schizophrenia Market Report: 

  • The Schizophrenia market size was valued ~USD 7,972 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In September 2024, Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has granted approval for COBENFY™ (xanomeline and trospium chloride), an oral treatment for adult schizophrenia. COBENFY marks the first new class of medication in decades, offering a novel approach by specifically targeting M1 and M4 receptors in the brain, without blocking D2 receptors.

  • In May 2024, Teva and Medincell reported positive results from the Phase III SOLARIS trial, which evaluated the efficacy of TEV-‘749 (olanzapine), a once-monthly subcutaneous long-acting injectable for adults with schizophrenia. SOLARIS is a multinational, multicenter, randomized, double-blind, placebo-controlled study designed to assess the efficacy, safety, and tolerability of olanzapine extended-release injectable suspension for subcutaneous use in patients aged 18-65 with schizophrenia.

  • In March 2024, US-based biopharmaceutical company Acadia Pharmaceuticals announced that its Phase III ADVANCE-2 clinical trial evaluating pimavanserin for treating negative symptoms of schizophrenia failed to meet its primary endpoint. The 26-week, placebo-controlled trial enrolled 454 adult participants with negative symptoms of schizophrenia who had stable control of positive symptoms through ongoing antipsychotic therapy.

  • The US holds the largest market share for schizophrenia, valued at approximately USD 5,749 million, compared to the EU4 (Germany, Italy, France, and Spain), the UK, and Japan.

  • In 2022, Germany had the largest schizophrenia market size among the EU4 and the UK, at approximately USD 432 million. This market is expected to grow further, with Germany projected to maintain the largest share, followed by the UK, by 2034.

  • In 2022, Japan’s schizophrenia market was valued at approximately USD 676 million, making it the second largest market. This is expected to grow further by 2034.

  • According to DelveInsight’s analysis, the total diagnosed prevalent cases of schizophrenia in the 7MM were approximately 3,796,850 in 2022, and this number is expected to rise throughout the study period (2020–2034).

  • DelveInsight’s analysis estimates that in 2022, the EU4 and the UK accounted for the largest share, approximately 42%, of the total diagnosed prevalent schizophrenia cases in the 7MM. These cases are expected to increase further by 2034.

  • DelveInsight analysts reported that in 2022, the gender-specific diagnosed prevalent cases of schizophrenia in the US were approximately 757,469 for males and 655,002 for females. These numbers are expected to fluctuate throughout the forecast period (2024-2034).

  • Key Schizophrenia Companies: Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others

  • Key Schizophrenia Therapies: RP5063 (brilaroxazine), MIN-101 (roluperidone), KarXT (xanomeline-trospium), NUPLAZID (pimavanserin), ICELPERTIN (BI-425809), SEP-363856 (ulotaront), OKEDI (risperidone ISM), LYN-005, NW-3509/NW-3509A (evenamide), CVL-231 (emraclidine), Seroquel Sustained Release, Intramuscular Olanzapine Depot, Xanomeline and Trospium Chloride Capsules, NBI-1117568, and others

  • The Schizophrenia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Schizophrenia pipeline products will significantly revolutionize the Schizophrenia market dynamics.

 

Schizophrenia Overview

Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. Individuals with schizophrenia may have difficulty distinguishing between what is real and what is imaginary, often experiencing delusions, hallucinations, disorganized thinking, and agitated body movements.

 

Get a Free sample for the Schizophrenia Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/schizophrenia-market

 

Schizophrenia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Schizophrenia Epidemiology Segmentation:

The Schizophrenia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Schizophrenia

  • Prevalent Cases of Schizophrenia by severity

  • Gender-specific Prevalence of Schizophrenia

  • Diagnosed Cases of Episodic and Chronic Schizophrenia

 

Download the report to understand which factors are driving Schizophrenia epidemiology trends @ Schizophrenia Epidemiology Forecast

 

Schizophrenia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Schizophrenia market or expected to get launched during the study period. The analysis covers Schizophrenia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Schizophrenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Schizophrenia Therapies and Key Companies

  • RP5063 (brilaroxazine): Reviva Pharmaceuticals

  • MIN-101 (roluperidone): Minerva Neurosciences

  • KarXT (xanomeline-trospium): Karuna Therapeutics

  • NUPLAZID (pimavanserin): Acadia Pharmaceuticals

  • ICELPERTIN (BI-425809): Boehringer Ingelheim

  • SEP-363856 (ulotaront): Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical

  • OKEDI (risperidone ISM): Laboratorios Farmacéuticos Rovi

  • LYN-005: Lyndra Therapeutics

  • NW-3509/NW-3509A (evenamide): Newron Pharmaceuticals

  • CVL-231 (emraclidine): Cerevel Therapeutics

  • Seroquel Sustained Release: AstraZeneca

  • Intramuscular Olanzapine Depot: Eli Lilly and Company

  • Xanomeline and Trospium Chloride Capsules: Karuna Therapeutics

  • NBI-1117568: Neurocrine Biosciences

 

Discover more about therapies set to grab major Schizophrenia market share @ Schizophrenia Treatment Landscape

 

Schizophrenia Market Drivers

  • Increasing popularity among individuals for long-acting injectable (LAI) antipsychotics are key factors driving growth of the global schizophrenia drugs market.

 

Schizophrenia Market Barriers

  • WHO’s Comprehensive Mental Health Action Plan 2013- 2030 will further enhance the awareness about mental health by ensuring 100 million more people have access to quality and affordable care for mental health conditions.

 

Scope of the Schizophrenia Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Schizophrenia Companies: Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others

  • Key Schizophrenia Therapies: RP5063 (brilaroxazine), MIN-101 (roluperidone), KarXT (xanomeline-trospium), NUPLAZID (pimavanserin), ICELPERTIN (BI-425809), SEP-363856 (ulotaront), OKEDI (risperidone ISM), LYN-005, NW-3509/NW-3509A (evenamide), CVL-231 (emraclidine), Seroquel Sustained Release, Intramuscular Olanzapine Depot, Xanomeline and Trospium Chloride Capsules, NBI-1117568, and others

  • Schizophrenia Therapeutic Assessment: Schizophrenia current marketed and Schizophrenia emerging therapies

  • Schizophrenia Market Dynamics: Schizophrenia market drivers and Schizophrenia market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Schizophrenia Unmet Needs, KOL’s views, Analyst’s views, Schizophrenia Market Access and Reimbursement 

 

To know more about Schizophrenia companies working in the treatment market, visit @ Schizophrenia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Schizophrenia Market Report Introduction

2. Executive Summary for Schizophrenia

3. SWOT analysis of Schizophrenia

4. Schizophrenia Patient Share (%) Overview at a Glance

5. Schizophrenia Market Overview at a Glance

6. Schizophrenia Disease Background and Overview

7. Schizophrenia Epidemiology and Patient Population

8. Country-Specific Patient Population of Schizophrenia 

9. Schizophrenia Current Treatment and Medical Practices

10. Schizophrenia Unmet Needs

11. Schizophrenia Emerging Therapies

12. Schizophrenia Market Outlook

13. Country-Wise Schizophrenia Market Analysis (2020–2034)

14. Schizophrenia Market Access and Reimbursement of Therapies

15. Schizophrenia Market Drivers

16. Schizophrenia Market Barriers

17.  Schizophrenia Appendix

18. Schizophrenia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion

Hydraulic Fluids Market Size, Emerging Trends, Development Status, and Business Opportunities & Top Key Players Analysis

“Browse 331 market data Tables and 58 Figures spread through 298 Pages and in-depth TOC on “Hydraulic Fluids Market”
The Hydraulic Fluids Market is experiencing steady growth, driven by increasing demand in industries such as construction, manufacturing, and automotive. Hydraulic fluids play a crucial role in machinery by transferring power efficiently while providing lubrication and reducing wear.

In terms of value, the hydraulic fluids market is estimated to grow from USD 8.7 billion in 2024 to USD 10.2 billion by 2029, at a CAGR of 3.2%. Hydraulic fluids market have grown as the demand from food processing end-use industry, and rising industrial growth in the Middle East & Africa and Asia Pacific region. These factors drive the hydraulic fluids market. 

The key players profiled in the report include Shell plc (UK), Exxon Mobil Corporation (US), BP p.l.c. (UK), Chevron Corporation (US), TotalEnergies SE (France), FUCHS SE (Germany) PetroChina Company Limited (China), ENEOS Holdings, Inc. (Japan), China Petroleum & Chemical Corporation (China), Idemitsu Kosan Co., Ltd. (Japan), and others. The hydraulic fluids market has witnessed insignificant growth in the past few years; government regulations and changing lifestyle drive the growth of this market. Market players are introducing new technologies, acquisitions, collaborations and features to acquire larger market shares.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71021039

Shell plc is one of the world’s largest oil & gas companies. It operates its operations with their five business segments, namely, integrated gas, renewables & energy solutions, marketing, chemical & products, and upstream. The company offers its hydraulic fluids for a wide range of end-use industries including construction, power generation, food processing, cement manufacturing and among others. It operates with 6 base oil storage hubs, 10 grease plants, 32 blending plants, and 4 base oil manufacturing plants. It has strong presence in European, North American, South American, the Middle East & Africa, and Asia Pacific region. In January 2024, shell plc plc acquired the Environmentally Considerate Lubricants (ECLs) business from the PANOLIN Group, which has subsidiaries in Switzerland, the UK, the US, and Sweden.

Exxon Mobil Corporation is a global specialty oil & gas company and also one of the largest companies in standings of revenue generation. The company is a global leader for synthetic oil technology and markets its hydraulic fluids products globally with brands such as Exxon, Mobil, and Esso. It has strong presence globally in more than 160 countries. It operated with five business segments, energy products, upstream, chemical products, specialty products, and corporate & financing. The company owns 6 base stock refineries and 21 blending plants in 25 countries which are present in almost all regions. In May 2024, Exxon Mobil Corporation acquired Pioneer Natural Resources Company to establish a unique, unconventional business in the Permian Basin.

Get Sample Copy of this Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=71021039

Synthetic oil is estimated to be the largest base oil type of hydraulic fluids market, in terms of value, during the forecast period.

The second-largest base oil type for the hydraulic fluids is synthetic oil based lubricants due to better performance over the mineral oil in extreme applications. Moreover, their life span is longer than that of air-cooled types, they perform well within both high as well as low temperatures, and they perform a better duty to keep machinery safeguarded. Although they are slightly more expensive initially, their capacity to elongate service times and protect expensive parts within automobiles and aircrafts make them an economical decision for business within the automotive, aerospace, as well as industrial categories. Due to these reasons, they are popular and commonly used in various end-use industries due to their high performance and lower initial and maintenance costs in the long run. As such, the synthetic oil based lubricants established for steady growth based on the certain complex issues of market on one hand and total solution approach on the other hand with special focus on natural and sustainable lubricants.

Europe is estimated to be the second-largest market for the hydraulic fluids market, in terms of value, in 2023.

Europe is the second-largest consumer region for hydraulic fluids. Being home to highly developed industrial segments, Europe holds the second position in terms of the hydraulic fluids consumption. The area has a fairly large manufacturing sector, thus automotive, aerospace and machinery industries, and among others has always need good lubricants for the smooth running and durability of machinery. Also, it is necessary to mention that Europe gives high importance to environmental concerns and energy savings; therefore, today this region demands high-quality environment-friendly advanced lubricants.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=71021039

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. 

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/hydraulic-fluid-market-71021039.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hydraulic Fluids Market Size, Emerging Trends, Development Status, and Business Opportunities & Top Key Players Analysis

BeamMed Inc. to Showcase Innovative Bone Density Scanner at NAACOS Fall 2024 Conference

“MiniOmni Portable Bone Density Scanner”
BeamMed Inc. is excited to announce its participation as an exhibitor at the NAACOS Fall 2024 Conference, held from October 16–18, 2024, at the prestigious Marriott Marquis in Washington, D.C. This premier event, organized exclusively by Accountable Care Organizations (ACOs), is a must-attend for healthcare professionals, offering two days of in-person sessions, pre-conference activities, and unparalleled networking opportunities.

NAACOS conferences are renowned for bringing together key stakeholders, including officials from the Centers for Medicare & Medicaid Services (CMS), ACO leaders, and policy insiders. This year’s fall event promises to provide invaluable insights into the future of healthcare delivery and policy, fostering collaboration among participants, speakers, and vendors.

At this pivotal event, BeamMed Inc. will be showcasing its innovative MiniOmni Portable Bone Density Scanner, a state-of-the-art solution designed to enhance patient care and operational efficiency. The MiniOmni is a fast, accurate, and portable bone density scanner that meets the criteria for HEDIS Osteoporosis Management in Women (OMW) and HEDIS Osteoporosis Screening in Older Women (OSW) measures. This cutting-edge technology offers healthcare providers a reliable tool for early detection and management of osteoporosis, thereby improving patient outcomes and reducing healthcare costs.

“We are thrilled to participate in the NAACOS Fall 2024 Conference,” said Gilad Zamir, VP of Sales at BeamMed Inc. “Our MiniOmni Portable Bone Density Scanner is designed to help healthcare providers deliver superior care with enhanced accuracy and efficiency. We look forward to connecting with ACO leaders and demonstrating how our technology can support their efforts in achieving better health outcomes for their patients.”

BeamMed Inc. invites all conference attendees to visit their exhibit booth to experience a live demonstration of the MiniOmni scanner and to learn more about its benefits in clinical practice. Attendees will have the opportunity to interact with BeamMed representatives, ask questions, and explore how this innovative technology can be integrated into their care models to enhance patient care quality and compliance with HEDIS measures.

For more information about BeamMed Inc. and the MiniOmni Portable Bone Density Scanner, please visit us at www.beammed.com

About BeamMed Inc.

BeamMed Inc. is a leading medical technology company dedicated to advancing bone health assessment solutions. With a commitment to innovation, accuracy, and portability, BeamMed Inc. has revolutionized bone density scanning, providing healthcare providers with state-of-the-art devices that enhance patient care and outcomes now, with rental options available.

Media Contact
Company Name: BeamMed Ltd.
Contact Person: Gilad Zamir
Email: Send Email
Phone: 800-769-6808
Address:950 S. Pine Island Road
City: Plantation
State: Florida
Country: United States
Website: www.beammed.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: BeamMed Inc. to Showcase Innovative Bone Density Scanner at NAACOS Fall 2024 Conference

Investors Alert: EMCORE (NASDAQ: EMKR), AGBA Group (NASDAQ: AGBA), Peraso Inc. (NASDAQ: PRSO) and CS Diagnostics (OTC: FZRO) Surge on Game-Changing News

EMCORE Corporation (NASDAQ: EMKR) saw its shares soar today following a major announcement from Mobix Labs (NASDAQ: MOBX). Mobix Labs, a leader in advanced wireless solutions for military and defense, has submitted a proposal to acquire all outstanding shares of EMCORE for $3.80 per share in cash, positioning itself as a key player in the aerospace and defense sectors. This move could provide immediate value to shareholders, making it an attractive opportunity for those looking to capitalize on this offer. Read more. 

In parallel, Peraso Inc. (NASDAQ: PRSO) has made significant strides with new strategic purchase orders, including deals with a Kenyan internet provider for its DUNE platform and a Korean contract to supply high-speed internet technology on trains. Additionally, Peraso secured a major military contract, further cementing its leadership in the 60 GHz mmWave technology market. Analysts at Benchmark have issued a “Buy” rating with a $4 price target, projecting strong growth fueled by its global expansion and military contracts. With a projected revenue surge in FY25, Peraso is a company investors should keep on their radar.  Read entire report. 

AGBA Group Holding Limited (NASDAQ: AGBA) also announced a pivotal moment in its growth trajectory with an amended merger agreement with Triller Corp. AGBA is expanding into high-growth social media and entertainment sectors through Triller’s AI-powered platform, unlocking new revenue channels such as pay-per-view and influencer sponsorships. This merger not only increases AGBA’s revenue potential but also positions it for significant global growth. For investors looking to capitalize on a diversified, tech-driven company with strong growth prospects, AGBA offers a timely investment opportunity. 

CS Diagnostics Group (OTC: FZRO) has surged from its July 2024 low of $0.20 to close at $3.10 on September 27, 2024, after a landmark agreement to sell and transfer its CS Protect-Hydrogel assets, including patents, to CS Diagnostics Corp. The hydrogel, designed to protect healthy tissues during radiation therapy, received a valuation exceeding €960 million, supported by the precedent of a similar product acquired by Boston Scientific for $500 million in 2018. As part of the transaction, CS Diagnostics Corp. issued 110 million shares of common stock, equating to a $500 million payment—making this a stock to watch closely. 

With EMCORE Corporation (NASDAQ: EMKR) poised for acquisition, Peraso Inc.’s (NASDAQ: PRSO) global expansion, AGBA Group’s (NASDAQ: AGBA) strategic merger with Triller and CS Diagnostics Group (OTC: FZRO) a stock to watch. These companies are positioned for strong growth and value creation. Now is the time for forward-thinking investors to take action and seize the opportunities presented by these market movers.

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Investors Alert: EMCORE (NASDAQ: EMKR), AGBA Group (NASDAQ: AGBA), Peraso Inc. (NASDAQ: PRSO) and CS Diagnostics (OTC: FZRO) Surge on Game-Changing News

Chronic Spontaneous Urticaria Treatment Market Size in the 7MM was ~USD 2200 Million in 2023, estimated DelveInsight

Chronic Spontaneous Urticaria Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Chronic Spontaneous Urticaria Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Chronic Spontaneous Urticaria Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Chronic Spontaneous Urticaria, historical and forecasted epidemiology as well as the Chronic Spontaneous Urticaria market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Chronic Spontaneous Urticaria Market by downloading the comprehensive report from DelveInsight @ Chronic Spontaneous Urticaria Treatment Market Size

 

Key Takeaways from the Chronic Spontaneous Urticaria Market

  • In September 2024:- Celldex Therapeutics- The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
  • In September 2024:- Taizhou Mabtech Pharmaceutical Co.,Ltd- This study is a multicenter, randomized, double-blind, positive parallel controlled phase III clinical trial to compare efficacy, immunogenicity, pharmacokinetics, pharmacodynamics and safety of omalizumab α(CMAB007) and Xolair® in patients with refractory chronic spontaneous urticaria.
  • The increase in Chronic Spontaneous Urticaria Market Size is a direct consequence of expected approval of emerging therapies and increasing awareness of chronic spontaneous urticaria in the 7MM.
  • As per DelveInsight analysis, there were approximately 4.1 million diagnosed prevalent cases of chronic urticaria, in the 7MM, in 2023. These cases are projected to increase during the forecast period (2024-2034).
  • According to DelveInsight analysis, there were around 138 thousand male and 381 thousand female cases of chronic spontaneous urticaria (CSU) in the US in 2023, with numbers expected to rise by 2034.
  • As per DelveInsight analysis among EU4 and the UK, there was a higher female affected population e.g. Germany accounted for around 97 thousand males and 229 thousand females affected by CSU in 2023. These cases are expected to change during the forecast period (2024-2034).
  • As per DelveInsight’s epidemiology model, among EU4 and the UK, the ≥60 age group had the highest number of CSU cases contributing to nearly 31% of the total cases, while the
  • The leading Chronic Spontaneous Urticaria Companies such as Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company and others.
  • Promising Chronic Spontaneous Urticaria Therapies such as barzolvolimab, CMAB007, Xolair, Dupilumab, LOU064 (blinded), and others.

 

Gain a competitive edge in the Chronic Spontaneous Urticaria Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Chronic Spontaneous Urticaria Treatment Drugs

 

Chronic Spontaneous Urticaria Epidemiology Segmentation in the 7MM

  • Total Chronic Spontaneous Urticaria Diagnosed Prevalent Cases
  • Chronic Spontaneous Urticaria Type-specific Cases
  • Chronic Spontaneous Urticaria Gender-specific Cases
  • Chronic Spontaneous Urticaria Age-specific Cases
  • Chronic Spontaneous Urticaria Severity-specific Cases

 

Chronic Spontaneous Urticaria Treatment Market

The treatment of CSU is challenging, and the therapeutic goal is a reduction in disease activity, complete symptom control, and improvement in QoL. The current treatment regime aims to alleviate symptoms and prevent their recurrence. The treatment pattern typically involves a step-wise approach, starting with first-line treatments and progressing to more advanced options if necessary. Treatment is generally initiated with nonsedating antihistamines in the daytime and sedating antihistamines at night. H2-antihistamines are often combined with H1 to achieve better symptom control in CSU and are added if individuals complain of indigestion or acidity. The most commonly used H2 antihistamine for CSU is ranitidine. However, it is important to note that ranitidine has been withdrawn from many markets due to safety concerns. Many patients, however, do not achieve symptom control, with only less than half of patients responding to H1-antihistamines at standard doses. Adverse effects such as somnolence can occur in susceptible individuals, increasing the treatment burden, despite increasing the dose.    

 

Discover key developments and opportunities in the Chronic Spontaneous Urticaria Market. Click here to learn more from DelveInsight’s latest report @ Chronic Spontaneous Urticaria Market Size

 

Chronic Spontaneous Urticaria Marketed Drugs

  • XOLAIR (omalizumab): Roche/Novartis
  • DUPIXENT (dupilumab): Sanofi/Regeneron

 

Chronic Spontaneous Urticaria Emerging Drugs Profile

  • Remibrutinib (LOU064): Novartis Pharmaceuticals
  • TEZSPIRE (tezepelumab): AstraZeneca/Amgen
  • Rilzabrutinib (SAR444671): Sanofi

 

Chronic Spontaneous Urticaria Therapeutics Market Landscape

Chronic spontaneous urticaria is a chronic condition characterized by the recurrent appearance of hives or wheals on the skin. It is a disturbing allergic condition of the skin, where symptoms persist for more than 6 weeks. The diagnosis is based on a physical examination and medical history. Additional tests are performed to rule out underlying causes or to identify triggers, such as blood tests, allergy tests, or skin biopsies. Treating chronic spontaneous urticaria is challenging, and the therapeutic goal is a reduction in disease activity, complete symptom control, and improvement in QoL. The current treatment regime aims to alleviate symptoms and prevent their recurrence. The treatment pattern typically involves a stepwise approach, starting with first-line treatments and progressing to more advanced options if necessary.

 

Chronic Spontaneous Urticaria Market Outlook

Chronic spontaneous urticaria is a disturbing allergic condition of the skin where symptoms persist for more than 6 weeks. A mast cell-driven disease is characterized by recurrent itchy wheals (hives) that may accompany angioedema. It often causes huge socio-economic distress for the patients, significantly impacting their quality of life. Treating chronic spontaneous urticaria is challenging, and the therapeutic goal is a reduction in disease activity, complete symptom control, and improvement in QoL. The current treatment regime aims to alleviate symptoms and prevent their recurrence. The treatment pattern typically involves a stepwise approach, starting with first-line treatments and progressing to more advanced options if necessary.

 

Download DelveInsight’s Chronic Spontaneous Urticaria Market report today and stay ahead in this rapidly evolving field. @ Chronic Spontaneous Urticaria Clinical Trials

 

Scope of the Chronic Spontaneous Urticaria Market Report

  • Coverage- 7MM
  • Chronic Spontaneous Urticaria Companies- Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company and others.
  • Chronic Spontaneous Urticaria Therapies- Barzolvolimab, CMAB007, Xolair, Dupilumab, LOU064 (blinded), and others.
  • Chronic Spontaneous Urticaria Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Chronic Spontaneous Urticaria Unmet Needs, KOL’s views, Analyst’s views, Chronic Spontaneous Urticaria Market Access and Reimbursement

 

Download the report to understand which factors are driving Chronic Spontaneous Urticaria Market Trends @ Chronic Spontaneous Urticaria Market Trends

 

Table of Content

1. Key Insights

2. Report Introduction

4. Methodology of Chronic Spontaneous Urticaria Epidemiology and Market

5. Executive Summary of Chronic Spontaneous Urticaria

6. Key Events

7. Disease Background and Overview

8. Patient Journey

9. Epidemiology and Patient Population

10. Marketed Drugs

11. Emerging Drugs

12. Chronic Spontaneous Urticaria: Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT

15. Unmet needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Spontaneous Urticaria Treatment Market Size in the 7MM was ~USD 2200 Million in 2023, estimated DelveInsight

Introducing Kradle.io: The Future of Property Management

September 30, 2024 – Today we are thrilled to announce the launch of Kradle.io, our groundbreaking SaaS platform that transforms property management for landlords and tenants alike. Created with security, ease of use, and support at its core, Kradle.io promises a property management experience as comforting and secure as its namesake.

Key Features of Kradle.io:

  • Dashboard: Our intuitive dashboard gives property managers a real-time overview of their properties, streamlining tasks and simplifying workflows.
  • Property Management: From tenant tracking to contract handling, our tools make managing your properties more efficient than ever.
  • Maintenance Management: With our system, reporting and resolving maintenance issues is quicker and more streamlined, with automatic updates keeping everyone in the loop.
  • Payment Processing: We offer a secure, multi-channel payment system that makes transaction management smooth and hassle-free.
  • Calendar: Integrated scheduling tools help keep track of key dates, from lease renewals to maintenance appointments.
  • Messaging: Our built-in messaging system enhances communication between tenants and landlords, ensuring clear, timely interactions.
  • Leasing Management: Automate the entire leasing process, reducing paperwork and saving time with digital document management and e-signatures.


What is next for Kradle.io? 

We are not stopping here. Over the coming months, Kradle.io will roll out several exciting new features:

  • AI-powered Predictive Maintenance: Imagine knowing about maintenance issues before they happen. Our AI tools will make it possible.
  • Blockchain for Secure Transactions: We are enhancing transaction security with blockchain technology, ensuring that every transaction is transparent and tamper-proof.
  • Advanced Tenant Screening: Our comprehensive screening processes are about to get even better, helping you choose the best tenants easily.
  • Streamlined Rent and Eviction Management: We will simplify how you collect rent and manage evictions, making these processes as smooth as possible.
  • Holistic Wellness Programs: Because community matters, we are introducing programs aimed at enhancing tenant well-being and fostering a vibrant community spirit.


Our Mission: “At Kradle, we aim to provide a rental experience that feels safe, supportive, and straightforward, guiding tenants and landlords smoothly from the start of a lease to its conclusion.”

For anyone managing rental properties, Kradle.io is more than just a tool — it is a partner in property management. Visit us at Kradle.io to learn more about how we can help you manage your properties more effectively.

We cannot wait to show you how Kradle.io is changing the game in property management. Join us as we continue to innovate and improve the rental experience for everyone.

Media Contact
Company Name: Kradle.io
Contact Person: Bishoy Girgis
Email: Send Email
Phone: 732-816-5059
Address:35 Equestrian Way
City: Monroe
State: New Jersey
Country: United States
Website: kradle.io

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Introducing Kradle.io: The Future of Property Management

Project Portfolio Management Market Recent Trends, Size, Share, Growth, Industry Analysis, Advance Technology And Forecast – 2029

“Oracle (US), Smartsheet (US), Microsoft (US), Asana (US), ServiceNow (US), Planview (US), SAP (Germany), Atlassian (Australia), Wrike (US), Monday.com (Israel), GFT Technologies (Germany), Adobe (US), Workday (US), OpenText (Canda).”
Project Portfolio Management (PPM) Market by Application (Project Planning & Management, Strategic Portfolio Management, Budget & Financial Management, Resource & Capacity Optimization, Reporting & Analytics) – Global Forecast to 2029.

The project portfolio management market is projected to expand at a Compound Annual Growth Rate (CAGR) of 11.9% over the forecast period, increasing from USD 7.8 billion in 2024 to USD 13.7 billion by 2029. This growth is driven by the market’s capacity to enhance project visibility, optimize resources, and improve decision-making through a unified platform that enables the efficient governance of multiple projects.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=225932595  

“As per application, the strategic portfolio management will grow at the highest CAGR during the forecast period.”

SPM is one of the most essential tools in the PPM sector and focuses on strategic orientation in investment in projects, which supports value enhancement of organizations and leads to business success. Regarding this, Strategic Portfolio Management empowers the organization to manage and communicate their projects sufficiently effectively and prioritize through optimized portfolio processes so that resources can be paid towards those most influential initiatives. SPM focuses on strategic alignment in connecting projects with an organization’s long-term objectives, fostering a single approach to realizing business success. Similarly, governance and compliance are used to promote control over projects and ensure that what is delivered aligns with the set industry and organizational standards. Such an all-inclusive approach enables decision-making and reduces risk through which strategic goals can be achieved with effective optimization of the project portfolio management process.

“As per vertical, IT & telecom holds the largest share during the forecast period.”

The IT & telecom industry is one of the key segments in the PPM market, mainly comprising complex and large projects. In the IT industry, the need for PPM solutions is relatively high for managing software development projects effectively so that proper control can be exercised over time, budget, and resources. Thus, PPM tools get heavily involved in telecommunication activities, whether network expansion, infrastructure up-gradation, or technology rollouts, due to the features available for task coordination, risk management, and strategic alignment. Furthermore, PPM is also utilized within the telecom industry to drive operational optimization and improve customer service and satisfaction. This vertical’s increased use of PPM solutions is necessitated due to better project visibility, resource optimization, and harmony with the set business objectives.

“As per region, Asia Pacific will grow at the highest CAGR during the forecast period.”

The PPM market in the Asia Pacific region is rapidly expanding, driven by established economies like China, Japan, and Australia and emerging markets such as India. Foreign investments are pivotal in this growth, bolstering economic development and fostering SME growth. In 2023, India’s Ministry of Electronics and Information Technology reported a 12% increase in IT spending, reflecting the region’s commitment to technological advancement and PPM solutions. China’s vast telecom sector, a leading global electronics supplier, is experiencing rising demand for PPM solutions to enhance resource management and business analytics. The market is further propelled by frequent project delays, workforce shortages, and a growing number of first-time users, particularly in the BFSI and government sectors. Significant investments are also being made in cloud computing and mobile work environments, with Singapore allocating USD 4.4 billion for digital infrastructure improvements. These factors collectively position Asia Pacific as a critical player in the global PPM market, driven by its solid technological foundation and strategic financial investments.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=225932595  

Unique Features in the Project Portfolio Management Market

One of the unique features driving the growth of the project portfolio management (PPM) market is the ability to provide better project visibility. PPM tools offer real-time insights into the status, progress, and performance of individual and collective projects. This transparency allows stakeholders to make informed decisions, track project milestones, and address bottlenecks effectively.

Another distinctive feature of the PPM market is its focus on resource optimization. PPM solutions enable organizations to allocate and manage resources efficiently across multiple projects. By tracking resource availability, workloads, and utilization, companies can ensure that they are maximizing their human, financial, and technological resources.

The PPM market also stands out due to its ability to facilitate superior decision-making. By providing a centralized platform with comprehensive data and analytics, PPM tools enable project managers and executives to make data-driven decisions. This includes the ability to prioritize projects, manage risks, and forecast future project outcomes.

A key feature that distinguishes PPM solutions is the integration of a single platform for governance across multiple projects. This platform consolidates all relevant information, making it easier to manage and oversee numerous projects simultaneously. It ensures that all projects adhere to established governance frameworks, maintaining compliance, reducing redundancies, and ensuring alignment with broader organizational objectives.

Major Highlights of the Project Portfolio Management Market

This significant growth is fueled by the increasing demand for efficient project management solutions across industries as organizations seek to streamline operations and maximize return on investment.

One of the major highlights in the PPM market is the rising adoption of cloud-based PPM solutions. Cloud platforms provide scalable, cost-effective solutions with enhanced accessibility, enabling teams to collaborate on projects from any location. This trend is especially crucial in an era of remote work and globalized teams, making cloud-based PPM tools a vital asset for organizations looking for agility and flexibility in project management.

Another key highlight is the growing emphasis on data-driven decision-making within the PPM market. Advanced analytics and real-time reporting tools provided by PPM solutions empower organizations to make informed decisions regarding resource allocation, project prioritization, and risk management. By leveraging data insights, companies can enhance project performance, mitigate risks, and improve overall business outcomes.

The incorporation of artificial intelligence (AI) and automation into PPM solutions is a transformative highlight of the market. AI-powered tools help automate routine tasks, predict project outcomes, and offer intelligent recommendations for resource management and risk mitigation.

Organizations are increasingly seeking strategic portfolio management (SPM) capabilities within PPM tools. This approach allows businesses to align their project portfolios with long-term strategic goals, ensuring that the right projects are prioritized and resources are allocated effectively.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=225932595  

Top Companies in the Project Portfolio Management Market

Major vendors in this market are in North America and Europe. Oracle, Smartsheet, Microsoft, Asana, and ServiceNow are among the leading project portfolio management market players. These firms have implemented a variety of growth tactics to increase their market position. These can include product launches, contracts, collaborations, mergers & acquisitions, and geographical expansion through new product development efforts.

Oracle

Oracle is an international corporation that deals in the development of software for database, cloud-based products, and software solutions for enterprises. The company is best known for its Oracle Database and Oracle Cloud Infrastructure and has diverse operations, from enterprise resource planning to customer experience and human capital management. It has a complete stack of PPM solutions primarily in the driving seat under its Oracle Primavera and Oracle Cloud offerings. On the other hand, Oracle Cloud facilitates rich functionalities in project planning, budgeting, resource management, collaboration tools, and real-time performance insights. Now, after it has been dramatically infused with specialization from Oracle, Primavera comes with advanced features for project scheduling, planning, resource management, and risk analysis for the construction and engineering sectors. In addition, seamless collaboration, as provided by its integration with cloud-based platforms, ensures project data is accessible from anywhere to improve a project’s decision-making and operational efficiency. Currently, its PPM solutions are used by many customers across over 175 countries, including those in sectors like construction, engineering, manufacturing, health care, finance, and the public sector. Large organizations employ Oracle’s PPM solutions to manage complex projects, optimize resources, and ensure timely completion.

Smartsheet

Organizations worldwide utilize Smartsheet as a platform for project management and automation. Smartsheet is recognized for its intuitive interface and blends the versatility of spreadsheets with powerful project management capabilities, catering to small teams and large corporations in different sectors. The interface features consist of Gantt charts to visually display project timelines, collaboration tools for instant teamwork, automated workflow management, and customizable reporting for monitoring project progress and results. Smartsheet’s PPM tool improves project planning, execution, and teamwork by prioritizing projects according to strategic alignment and resource availability. The centralized reporting and dashboards provided by the company enhance decision-making and efficiency. It caters to various industries like technology, healthcare, construction, and manufacturing for project scheduling, resource distribution, portfolio supervision, and compliance documentation, promoting efficient collaboration and openness during the project’s duration.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103
City: Delray Beach
State: FL 33445
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/project-portfolio-management-software-market-225932595.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Project Portfolio Management Market Recent Trends, Size, Share, Growth, Industry Analysis, Advance Technology And Forecast – 2029

TellMeWhereItHurtsNow.com Launches Innovative 3D Pain Mapping Tool

TellMeWhereItHurtsNow.com Launches Innovative 3D Pain Mapping Tool

TellMeWhereItHurtsNow.com introduces an improved 3D pain mapping tool, designed to help patients communicate their discomfort more effectively.
TellMeWhereItHurtsNow.com introduces an improved 3D pain mapping tool, designed to help patients communicate their discomfort more effectively.

TellMeWhereItHurtsNow.com introduces an improved 3D pain mapping tool, designed to help patients communicate their discomfort more effectively. Born from a personal need, this user-friendly digital solution aims to enhance the dialogue between individuals and their healthcare providers. By allowing users to visually represent their pain points on a detailed body map, the tool offers a simple yet powerful way to track and share pain information, potentially leading to more informed discussions and tailored treatment plans.

Many patients experience difficulties in articulating the exact location and nature of their pain to healthcare professionals. This challenge prompted Tomas L., the creator of TellMeWhereItHurtsNow.com, to develop an innovative tool to facilitate clearer communication. The objective was to make it easier for patients to convey precise information to their healthcare providers.

The tool features a 3D model of the human body, enabling users to identify specific pain points with accuracy. This digital representation provides a clear and visual method for explaining pain locations during medical consultations. The ability to visually map out pain can lead to more efficient and productive appointments, ultimately contributing to better patient care.

Additionally, the tool includes a feature that allows users to track their pain over time. This functionality is particularly useful for those undergoing new treatment regimens, as they can monitor changes in their pain. The visual and interactive nature of the tool makes it an effective alternative to traditional pain diaries, offering a more engaging way to record and assess pain levels.

Designed to be accessible to all users, the tool is straightforward to navigate, ensuring that even those with limited technological skills can use it effectively. The development team at TellMeWhereItHurtsNow.com prioritized user-friendliness to ensure broad usability. Whether a patient is highly tech-savvy or less familiar with digital tools, they will find this pain mapping tool intuitive and easy to utilize.

This tool also presents significant advantages for healthcare providers. By visualizing a patient’s pain and tracking its progression, medical professionals can gain deeper insights into the patient’s condition. These insights can inform more accurate diagnoses and more effective treatment plans. Ultimately, the tool serves as a bridge to improve communication and collaboration between patients and their healthcare teams.

In summary, the new 3D pain mapping tool available on TellMeWhereItHurtsNow.com represents a valuable resource for both patients and healthcare providers. It addresses the common issue of pain communication, making it easier for patients to express their experiences and for healthcare professionals to understand and respond appropriately. This advancement underscores the importance of clear communication in healthcare and demonstrates a commitment to enhancing the patient care experience.

For individuals seeking a method to better communicate their pain or to track changes in their condition, this tool offers a comprehensive solution. Available now on TellMeWhereItHurtsNow.com, the 3D pain mapping tool stands as an innovative option to support effective dialogue and improved healthcare outcomes. Clear and effective communication with healthcare providers is crucial, and this new tool is poised to make a significant impact in that regard.

Media Contact
Company Name: Tell Me Where It Hurts Now.com
Contact Person: Tomas L., Founder
Email: Send Email
Country: United States
Website: TellMeWhereItHurtsNow.com

Documentary “the Sinking of the Lisbon Maru” releases WW2 British Prisoners Stories

With the screening of a film titled “The Sinking of the Lisbon Maru” on Sep. 6, a history hidden for 82 years has finally found its voice. It shares with us a bitter history rarely known to many.

In October 1942, the Japanese army requisitioned the passenger and cargo ship Lisbon Maru to transport more than 1,800 British prisoners of war back to Japan from Hong Kong. When passing through the waters near China’s Zhoushan, the ship was hit by the US army. As a result, 843 British prisoners lost their lives, and 384 were rescued by local fishermen. The British officers, soldiers, and government extended their heartfelt gratitude to the local people for their benevolence.

In 2014, when Fang Li and Han Han were filming “The Continent” on Dongji Island, they heard the story of the Lisbon Maru. Driven by curiosity, Fang Li led a team to conduct a survey in 2016. They accurately located the wreck and confirmed by technical means that it was indeed the Lisbon Maru’s wreckage.

Fang Li quickly learned that the two living witnesses of the Lisbon Maru accident, Lin Agen from Dongji Island and British veteran Dennis Morley, were both in their 90s. Fang Li believed that both “human testimony and physical evidence” needed to be preserved, so he embarked on a journey of searching for witnesses in 2018.

Descendants of British prisoners of war communicate with Lin Agen (the third person on the right), a fisherman from Dongji Island who participated in the rescue

In the first week in the UK, Fang Li and his team encountered countless heartbreaking stories. These stories brought a profound emotional impact on Fang Li. Since the Lisbon Maru accident affected a total of 1,816 families of British prisoners of war and 255 Chinese fisherman families, Fang Li spent over RMB 2 million on full-page advertisements in the UK’s influential newspapers including The Sunday Times, The Guardian, and The Daily Telegraph, seeking British prisoners of war and their descendants involved in the Lisbon Maru accident.

The BBC (British Broadcasting Corporation) invited Fang Li for a live-stream interview, which evoked significant public repercussion. Following the interview, more than 380 descendants of the witnesses got in touch with Fang Li.

For two consecutive years, in 2018 and 2019, Fang Li focused on “rescue-oriented interviews”. Fang Li refused to act as an indifferent spectator. “When they see a Chinese who is highly empathetic with them, they are gradually willing to share anything with me.”

“The Sinking of the Lisbon Maru” is eventually presented as a documentary feature film.

Media Contact
Company Name: Sichuan International Communication Center
Contact Person: Ge Dan
Email: Send Email
Country: China
Website: https://www.center.top/detail/103912